Piramal Pharma Ltd on January 29 reported wider loss for the December quarter, hit by a combination of inventory destocking, weak early?stage CDMO orders and regulatory delays in its hospital generics portfolio.The drugmaker posted a consolidated net loss of Rs 136.19 crore after accounting for Rs 41 crore in exceptional items. The company reported a profit of Rs 4 crore in the year-ago period.Rev...

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, appointments, order wins, and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:Q1FY26 Earnings Update (Provisional)Bajaj Finance Q1 (YoY)Customer franchise as of June 2025 stood at 106.51 million Vs 88.11 million as of June 2024New loans boo...

The spotlight in global markets today is firmly on the Federal Reserve’s upcoming policy decision and forecasts, set to be unveiled late Wednesday night. While another quarter-point rate cut appears highly likely, the real focus is on the Fed’s strategy for 2025 as it works to balance inflation control with sustaining economic growth.And just when things couldn’t get trickier, enter the wild...

Morgan Stanley On WiproUnderweight Call, Target At `250/ShAfter Capco (2021) & Rizing (2022) Acquisition, See Applied Value Tech Acqn Being Relatively SmallSee The Acqn Supporting More Of Capability Boost & Adding Some Marquee Clients To PortfolioGiven Small Scale, See Acquisition Having A Limited Impact On Financials In FY25/FY26CLSA On ITTCS, Infosys & Wipro, In Their Quarterly Preview, Showed C...

Shares of Piramal Pharma soared as much as 5.5 percent in early trade on October 24, a day after the drugmaker reported solid earnings for the July-September quarter, marked by a steep surge in its net profit.At 09.38 am, shares of Piramal Pharma were trading at Rs 227.29 on the NSE.The drugmaker's net profit zoomed 3.5 times year-on-year to Rs 22.59 crore in the September quarter, up from Rs 5.02...